OBJECTIVE: Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was undertaken to evaluate the association of an increase in PR3-ANCA level with subsequent relapse. METHODS: Data from the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial were used. Starting from the time of achieving complete remission, serial measurements by direct and capture enzyme-linked immunosorbent assays (ELISAs) were analyzed in 93 patients with PR3-ANCA, using Cox proportional hazards regression. RESULTS: An increase in PR3-ANCA level was identified in 58 of 93 subjects (62.4%) by direct ELISA and in 59 of 93 (63.4%) by capture ELISA. Relapses occurred in 55 of 93 subjects (59.1%), with 25 and 21 occurring within 1 year after an increase by direct ELISA and capture ELISA, respectively. An increase by direct ELISA was associated with subsequent severe relapses (hazard ratio [HR] 4.57; P < 0.001), particularly in patients presenting with renal involvement (HR 7.94; P < 0.001) and alveolar hemorrhage (HR 24.19; P < 0.001). Both assays identified increased risk for severe relapse in the rituximab group (HR 5.80; P = 0.002 for direct ELISA and HR 4.54; P = 0.007 for capture ELISA) but not the cyclophosphamide/azathioprine group (P = 0.103 and P = 0.197, respectively). CONCLUSION: The association of an increase in PR3-ANCA level with the risk of subsequent relapse is partially affected by the PR3-ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3-ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3-ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy.
OBJECTIVE: Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was undertaken to evaluate the association of an increase in PR3-ANCA level with subsequent relapse. METHODS: Data from the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial were used. Starting from the time of achieving complete remission, serial measurements by direct and capture enzyme-linked immunosorbent assays (ELISAs) were analyzed in 93 patients with PR3-ANCA, using Cox proportional hazards regression. RESULTS: An increase in PR3-ANCA level was identified in 58 of 93 subjects (62.4%) by direct ELISA and in 59 of 93 (63.4%) by capture ELISA. Relapses occurred in 55 of 93 subjects (59.1%), with 25 and 21 occurring within 1 year after an increase by direct ELISA and capture ELISA, respectively. An increase by direct ELISA was associated with subsequent severe relapses (hazard ratio [HR] 4.57; P < 0.001), particularly in patients presenting with renal involvement (HR 7.94; P < 0.001) and alveolar hemorrhage (HR 24.19; P < 0.001). Both assays identified increased risk for severe relapse in the rituximab group (HR 5.80; P = 0.002 for direct ELISA and HR 4.54; P = 0.007 for capture ELISA) but not the cyclophosphamide/azathioprine group (P = 0.103 and P = 0.197, respectively). CONCLUSION: The association of an increase in PR3-ANCA level with the risk of subsequent relapse is partially affected by the PR3-ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3-ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3-ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy.
Authors: Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks Journal: Arthritis Rheum Date: 2012-11
Authors: Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon Journal: N Engl J Med Date: 2014-11-06 Impact factor: 91.245
Authors: Philip Seo; Yuan-I Min; Janet T Holbrook; Gary S Hoffman; Peter A Merkel; Robert Spiera; John C Davis; Steven R Ytterberg; E William St Clair; W Joseph McCune; Ulrich Specks; Nancy B Allen; Raashid A Luqmani; John H Stone Journal: Arthritis Rheum Date: 2005-07
Authors: E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Ding; D Iklé; M Villareal; N Lim; P Brunetta; F C Fervenza; P A Monach; J H Stone Journal: Arthritis Rheumatol Date: 2015-06 Impact factor: 10.995
Authors: Javier D Finkielman; Augustine S Lee; Amber M Hummel; Margaret A Viss; Gregory L Jacob; Henry A Homburger; Tobias Peikert; Gary S Hoffman; Peter A Merkel; Robert Spiera; E William St Clair; John C Davis; W Joseph McCune; Andrea K Tibbs; Steven R Ytterberg; John H Stone; Ulrich Specks Journal: Am J Med Date: 2007-07 Impact factor: 4.965
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01
Authors: Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel Journal: J Autoimmun Date: 2019-07-15 Impact factor: 7.094
Authors: J M Clain; A M Hummel; J H Stone; F C Fervenza; G S Hoffman; C G M Kallenberg; C A Langford; W J McCune; P A Merkel; P A Monach; P Seo; R F Spiera; E W St Clair; S R Ytterberg; U Specks Journal: Clin Exp Immunol Date: 2017-02-07 Impact factor: 4.330
Authors: Rennie L Rhee; John C Davis; Linna Ding; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; W Joseph McCune; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; John H Stone; Peter A Merkel Journal: Clin J Am Soc Nephrol Date: 2018-01-25 Impact factor: 8.237
Authors: Britta E Jones; Jiajin Yang; Akhil Muthigi; Susan L Hogan; Yichun Hu; Joshua Starmer; Candace D Henderson; Caroline J Poulton; Elizabeth J Brant; William F Pendergraft; J Charles Jennette; Ronald J Falk; Dominic J Ciavatta Journal: J Am Soc Nephrol Date: 2016-11-07 Impact factor: 10.121